1-9 of 9
Lisa Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PS5-25: Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms

Free
Daniel L Hertz, Karen Lisa Smith, Yuhua Zong, Christina L Gersch, Andrea Pesch, Arti Patel, Jennifer Lehman, N. Lynn Henry, Kelley M Kidwell, James M Rae, Vered Stearns
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS5-25.
https://doi.org/10.1158/1538-7445.SABCS20-PS5-25
Published: 15 February 2021
View article titled, Abstract PS5-25: Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms
Journal Articles

Abstract PD10-07: Patient reported outcomes and early discontinuation of adjuvant endocrine therapy according to neighborhood poverty rate

Free
Ramy Sedhom, Amanda Blackford, David Lim, Jennifer Ensminger, Claire Snyder, Vered Stearns, Karen Lisa Smith
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD10-07.
https://doi.org/10.1158/1538-7445.SABCS19-PD10-07
Published: 15 February 2020
View article titled, Abstract PD10-07: Patient reported outcomes and early discontinuation of adjuvant endocrine therapy according to neighborhood poverty rate
Journal Articles

Abstract 1728: Discovery of highly selective DUB inhibitors with in vivo pre-clinical anti-tumor activity

Free
Xavier Jacq, Niall MB Martin, Lisa Smith, Jeanine Harrigan, Charlotte Knights, Helen Robinson, Yaara Ofir-Rosenfeld, Aaron Cranston, Mark I. Kemp, Stephen P. Jackson
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1728.
https://doi.org/10.1158/1538-7445.AM2015-1728
Published: 01 August 2015
View article titled, Abstract 1728: Discovery of highly selective DUB inhibitors with in vivo pre-clinical anti-tumor activity
Journal Articles

Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity

Free
Xavier Jacq, Lisa Smith, Elaine Brown, Adina Hughes, Rajesh Odedra, Dan Heathcote, Jen Barnes, Steve Powell, Sharon Maguire, Victoria Pearson, Joana Boros, Peter Caie, Pia A. Thommes, Willem Nissink, Kevin Foote, Philip J. Jewsbury, Sylvie M. Guichard
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1823.
https://doi.org/10.1158/1538-7445.AM2012-1823
Published: 15 April 2012
View article titled, Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity
Journal Articles

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Free
Christine M. Chresta, Barry R. Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E. Critchlow, John P. Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richard Jenkins, Matt Jacobsen, Graeme C.M. Smith, Sylvie Guichard, Martin Pass
Journal: Cancer Research
Cancer Res (2010) 70 (1): 288–298.
https://doi.org/10.1158/0008-5472.CAN-09-1751
Published: 04 January 2010
View article titled, AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Open the PDF for AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract #4777: The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia

Free
Amy Johnson, Lisa Smith, Chelsey Raymond, David Lucas, Joseph Flynn, Malaz AbuTarif, Paul Statkevich, Rajat Bannerji, John Byrd
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4777.
Published: 01 May 2009
View article titled, Abstract #4777: The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia
Journal Articles

Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of rapamycin (mTOR)

Free
Ian Hickson, Lisa Smith, Sharon Maguire, Heather Duggan, Karine Malagu, Marc Hummersone, Keith Menear, Christine Chresta, Barry Davies, Martin Pass, Niall Martin, Graeme Smith
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1422.
Published: 01 May 2008
View article titled, Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of rapamycin (mTOR)
Journal Articles

Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets

Free
Laura J. Rush, Aparna Raval, Pauline Funchain, Amy J. Johnson, Lisa Smith, David M. Lucas, Melania Bembea, Te-Hui Liu, Nyla A. Heerema, Laura Rassenti, Sandya Liyanarachchi, Ramana Davuluri, John C. Byrd, Christoph Plass
Journal: Cancer Research
Cancer Res (2004) 64 (7): 2424–2433.
https://doi.org/10.1158/0008-5472.CAN-03-2870
Published: 01 April 2004
View article titled, Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets
Open the PDF for Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets in another window
Journal Articles

Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab

Free
John C. Byrd, Lisa Smith, Marcy L. Hackbarth, Ian W. Flinn, Donn Young, John H. Proffitt, Nyla A. Heerema
Journal: Cancer Research
Cancer Res (2003) 63 (1): 36–38.
Published: 01 January 2003
View article titled, Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab
Open the PDF for Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab in another window